Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 23, 2024

SELL
$41.33 - $74.26 $41 - $74
-1 Reduced 5.26%
18 $0
Q4 2023

Feb 08, 2024

SELL
$59.06 - $75.72 $649 - $832
-11 Reduced 36.67%
19 $1,000
Q3 2023

Oct 10, 2023

SELL
$65.94 - $99.04 $263 - $396
-4 Reduced 11.76%
30 $2,000
Q1 2023

Apr 25, 2023

SELL
$47.19 - $70.77 $5,426 - $8,138
-115 Reduced 77.18%
34 $2,000
Q1 2022

Apr 08, 2022

SELL
$57.56 - $82.54 $10,878 - $15,600
-189 Reduced 55.92%
149 $10,000
Q4 2021

Feb 09, 2022

SELL
$72.5 - $100.68 $1.02 Million - $1.42 Million
-14,110 Reduced 97.66%
338 $26,000
Q3 2021

Oct 12, 2021

SELL
$90.24 - $124.05 $77,696 - $106,807
-861 Reduced 5.62%
14,448 $1.38 Million
Q2 2021

Jul 12, 2021

BUY
$93.66 - $139.27 $91,318 - $135,788
975 Added 6.8%
15,309 $1.9 Million
Q1 2021

Apr 09, 2021

BUY
$116.57 - $155.01 $20,050 - $26,661
172 Added 1.21%
14,334 $1.89 Million
Q4 2020

Jan 06, 2021

SELL
$99.61 - $142.12 $2 Million - $2.85 Million
-20,073 Reduced 58.63%
14,162 $1.88 Million
Q3 2020

Oct 06, 2020

SELL
$72.92 - $102.01 $537,785 - $752,323
-7,375 Reduced 17.72%
34,235 $3.49 Million
Q2 2020

Jul 07, 2020

SELL
$55.75 - $92.75 $2.43 Million - $4.04 Million
-43,585 Reduced 51.16%
41,610 $3.62 Million
Q1 2020

Apr 06, 2020

BUY
$37.9 - $104.44 $2.62 Million - $7.23 Million
69,235 Added 433.8%
85,195 $4.94 Million
Q4 2019

Jan 10, 2020

BUY
$77.66 - $99.74 $1.24 Million - $1.59 Million
15,960 New
15,960 $1.48 Million
Q4 2018

Jan 11, 2019

SELL
$56.04 - $82.66 $5,604 - $8,266
-100 Closed
0 $0
Q2 2018

Jul 05, 2018

BUY
$37.84 - $69.96 $3,784 - $6,995
100 New
100 $6,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track American National Bank Portfolio

Follow American National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American National Bank, based on Form 13F filings with the SEC.

News

Stay updated on American National Bank with notifications on news.